Denali Therapeutics (DNLI) Return on Capital Employed: 2018-2024
Historic Return on Capital Employed for Denali Therapeutics (DNLI) over the last 7 years, with Dec 2024 value amounting to -0.37%.
- Denali Therapeutics' Return on Capital Employed fell 20.00% to -0.37% in Q4 2024 from the same period last year, while for Dec 2024 it was -0.37%, marking a year-over-year decrease of 20.00%. This contributed to the annual value of -0.42% for FY2024, which is 26.00% down from last year.
- Per Denali Therapeutics' latest filing, its Return on Capital Employed stood at -0.37% for Q4 2024, which was down 5.46% from -0.35% recorded in Q3 2024.
- Denali Therapeutics' 5-year Return on Capital Employed high stood at 0.05% for Q4 2020, and its period low was -0.40% during Q1 2020.
- Moreover, its 3-year median value for Return on Capital Employed was -0.32% (2024), whereas its average is -0.28%.
- Its Return on Capital Employed has fluctuated over the past 5 years, first spiked by 45bps in 2020, then tumbled by 37bps in 2022.
- Over the past 5 years, Denali Therapeutics' Return on Capital Employed (Quarterly) stood at 0.05% in 2020, then plummeted by 33bps to -0.28% in 2021, then dropped by 7bps to -0.35% in 2022, then rose by 17bps to -0.18% in 2023, then dropped by 20bps to -0.37% in 2024.
- Its last three reported values are -0.37% in Q4 2024, -0.35% for Q3 2024, and -0.33% during Q2 2024.